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Several studies suggest that the complement system is involved in atherogenesis. To further investigate this question, we have
studied the ability of native and modiﬁed forms of LDL to bind and activate C1, the complex protease that triggers the classical
pathway of complement. Unlike native LDL, oxidized (oxLDL) and enzymatically modiﬁed (E-LDL) derivatives were both
recognized by the C1q subunit of C1, but only E-LDL particles, obtained by sequential treatment with a protease and then with
cholesterol esterase, had the ability to trigger C1 activation. Further investigations revealed that C1q recognizes a lipid component
ofE-LDL.Severalapproaches,includingreconstitutionofmodellipidvesicles,cosedimentation,andelectron microscopyanalyses,
providedevidencethatC1bindingtoE-LDLparticlesismediatedbytheC1qglobulardomain,whichsensesunesteriﬁed fattyacids
generated by cholesterol esterase. The potential implications of these ﬁndings in atherogenesis are discussed.
1.Introduction
It is generally accepted that accumulation of low-density
lipoproteins (LDLs) in the extracellular matrix of the blood
vesselsisthestarting pointofatherogenesis[1].Nevertheless,
how this leads to chronic inﬂammation and injury of the
arterial wall is still poorly understood. The arterial intima
is known to contain a number of oxidative agents and
proteolytic enzymes, and these are thought to convert LDL
particles into the lipid droplets and vesicles found during
the early steps of atherogenesis [2–4]. Cell-induced oxidative
modiﬁcation or incubationin vitro with high concentrations
of transition metals such as copper yields LDL derivatives
endowed with atherogenic properties [5, 6]. On the other
hand, lipidparticles enriched in unesteriﬁed cholesterol have
been isolated from the arterial intima and found to be
structurally similar to the LDL derivative (E-LDL) generated
in vitro by sequential treatment with trypsin and cholesterol
esterase (CEase) [7, 8]. It has been hypothesized that the
oxidative and enzymatic modiﬁcations of LDL possibly
complement each other, E-LDL being involved in the early
steps of atherogenesis and oxidation playing a role in the
progression of the disease [9].
Complement, known to be a major arm of innate immu-
nity against pathogens, is also emerging as a potentially
important factor of atherosclerosis [10]. That LDL deriva-
tives have the ability to activate the complement system was
initially describedby Seifertand coworkers,who showed that
cholesterol-containing lipid particles isolated from human
atherosclerotic lesions activate complement to completion
[11]. It was later reported by the same group that, unlike
nativeLDLandoxidizedLDL(oxLDL),E-LDLhas theability
to activate complement both directly and in a C-reactive
protein- (CRP-) dependent manner [12]. Triggering of the
classical pathway of complement results from binding of the
C1complex,throughitsrecognitionsubunitC1q,toavariety
of immune and nonimmune targets and elicits activation of
its partner proteases C1r and C1s [13]. We have compared
the ability of oxLDL and E-LDL derivatives to interact with
the C1 complex, providing evidence that E-LDL eﬃciently2 Journal of Lipids
activates C1 under conditions close to the physiological
situation and is recognized by C1q [14]. More recently, we
have shown that C1q recognizes E-LDL particles through
unesteriﬁed fatty acids generated by cholesterol esterase
treatment[15].Theaimofthispaperistobrieﬂyreviewthese
ﬁndings, which shed new light on the interactions between
E-LDL and the classical pathway of complement and suggest
a possible implication of these interactions in atherogenesis.
2.ModiﬁedLipoproteinsDifferentiallyBind
and Activatethe C1ComplexofComplement
The ability of native and modiﬁed forms of LDL to trigger
activation of the C1 complex was tested in vitro by means
of a C1 activation assay in the presence of excess C1
inhibitorinorderto preventspontaneous C1activation[16].
Under these conditions, which are close to the physiological
situation, puriﬁed native LDL did not signiﬁcantly activate
C1. Likewise, oxLDL had no signiﬁcant activating eﬀect at
concentrations up to 1μM, even though slight activation
(about 10%) was observed in the presence of CRP. In
contrast, sequential treatment of native LDL with trypsin
and thenwith CEase endowedtheresulting E-LDL derivative
with the ability to trigger eﬃcient C1 activation [14]. The
activation level at 1μM E-LDL reached about 60%, and
activation was not sensitive to CRP. Sequential treatment of
LDL with trypsin and then CEase was critical to generate
a C1-activating particle, and proteases such as plasmin and
proteinase K were as eﬃcient as trypsin for this purpose.
The ability of C1q, the recognition unit of C1, to bind
native LDL and its modiﬁed forms was investigated by sur-
face plasmon resonance spectroscopy, using the lipoproteins
as immobilized ligands and C1q as the soluble analyte.
C1q did not show signiﬁcant binding to native LDL but
readily bound to both oxLDL and E-LDL. By recording
binding curves at varying C1q concentrations, as illustrated
in Figure 1 for E-LDL, the dissociation constants (KD)w e r e
determined. E-LDL and oxLDL each yielded values in the
nanomolar range (23–75nM), indicating that C1q binds
both derivatives with high aﬃnity [14].
In subsequent experiments [15], a series of proteolytic
enzymes known to be present in atherosclerotic lesions
were tested for their ability to generate C1-activating E-
LDL particles when used in conjunction with CEase. As
shown by SDS-PAGE analysis, in addition to trypsin,
plasmin, kallikrein, chymase, and thrombin all extensively
split the apolipoprotein B-100 (Apo-B100) of LDL, whereas
tryptase, and matrix metalloprotease-2 had milder eﬀects.
Subsequent incubation with CEase revealed that samples
initiallytreatedwithplasmin,thrombin,tryptase,andmatrix
metalloprotease-2 displayed a C1-activating ability compa-
rable to that obtained using trypsin, whereas chymase and
kallikrein had moderate or no eﬀect. Thus, initial treatment
of LDL with a protease was clearly a prerequisite to generate
C1-activating particles, but there was no strict correlation
between the extent of Apo-B100 degradation and the result-
ing C1 activation extent. Increasing the CEase concentration
and the incubation time both readily increased the C1-
activating ability of the resulting LDL particles, yielding
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Figure 1: Analysis by surface plasmon resonance spectroscopy of
the interaction between C1q and immobilized E-LDL. The E-LDL
derivative (14,000 resonance units) was immobilized chemically on
the surface of a CM5 sensor chip (GE Healthcare) and allowed to
bind to increasing concentrations of soluble C1q (100–600nM).
The KD value was determined from the ratio of the dissociation
and association rate constants (koﬀ/kon)( t a k e nf r o m[ 14], with
permission).
complete C1 activation after incubation of trypsin-treated
LDL with 320milliunits/mL CEase for 18h at 37◦C[ 15].
Thus, subsequent modiﬁcation of trypsin-treated LDL with
CEase was clearly a determinant step for generating particles
recognized by C1q and exhibiting C1-activating ability. In
contrast, treatment of native LDL with phospholipase A2 or
sphingomyelinase did not yield signiﬁcant C1 activation.
3.C1qRecognizesa LipidComponentof E-LDL
As a ﬁrst step towards identiﬁcation of the LDL compo-
nent(s) recognized by C1q, the lipid fractions of native LDL,
trypsin-treated LDL, and E-LDL were extracted and used to
prepare vesicles which were then tested for their ability to
activateC1[15].AsshowninFigure2,vesiclescontainingthe
lipid fraction of unmodiﬁed or trypsin-treated LDL did not
yield C1 activation. In contrast, vesicles prepared from LDL
samples treated with trypsin and then incubated with CEase
for increasing periods at 37◦C developed increasing C1-
activating ability, to reach about 90% activation after incu-
bation with 320milliunits CEase for 16h. In contrast, the
protein component of this sample left after lipid extraction
did not induce C1 activation. Likewise, native or trypsin-
treated ApoB-100 had no activating eﬀect.
As measured by reverse-phase HPLC, the lipid fraction
of native LDL contained a small amount of unesteriﬁed
cholesterol (398 ± 50nmol/mg of protein), as well as the
cholesteryl esters characteristic of LDL (22:6, 20:4, 18:2,
18:1, and 16:0). Incubation overnight at 37◦Cl e dt on e a r l y
complete disappearance of the cholesteryl ester peaks, with
concomitantly a raise of unesteriﬁed cholesterol to 3140 ±
160nmol/mg of protein. Analysis of the lipid fraction of the
E-LDL particles generated upon incubation for increasing
periods with CEase showed a good correlation between the
content in unesteriﬁed cholesterol and the extent of C1
activation. This suggested that cholesterol itself, or fatty
acids, or both of these molecules resulting from CEase
treatment could be recognized by C1q.Journal of Lipids 3
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Figure 2: C1 activation by E-LDL particle: correlation with the
amount of unesteriﬁed cholesterol generated. LDL (1mg/mL) was
treated with 20μg/mL trypsin for 2h at 37◦C and then with
320milliunits/mL CEase for the indicated periods at 37◦C. The
lipid fraction from each sample was extracted and incorporated
into vesicles. Each vesicle was tested for its C1-activating ability
(black bars). The cholesterol content of each lipid fraction (open
circles) was determined by reverse-phase HPLC. LDL: native LDL;
Try-LDL: trypsin-treated LDL (taken from [15], with permission).
4.C1q Recognizes E-LDL through Unesteriﬁed
FattyAcids Generated by CEase
To identify the lipid component(s) of E-LDL recognized
by C1q, E-LDL was treated with methyl-β-cyclodextrin
(MBCD),a reagent known to extract unesteriﬁed cholesterol
from membranes [15]. Incubation of E-LDL particles with
increasing concentrations of MBCD for 1h at 37◦Cp r o g r e s -
sively abolished their C1-activating ability. However, parallel
analyses by thin-layer chromatography clearly indicated
that MBCD not only depleted free cholesterol but also
removedunesteriﬁed fatty acids,yielding in bothcases>70%
depletion at an MBCD concentration of 2.25mM.
Incubation of the E-LDL particles with increasing con-
centrations of human serum albumin, a reagent known to
removeunesteriﬁed fattyacids, decreased their C1-activating
ability in a dose-dependent fashion, resulting in >60%
inhibitionupontreatmentwith10%(w/v)albumin.Analysis
bythin-layerchromatographyrevealedthattheC1-activating
ability of the samples roughly correlated with the extent of
unesteriﬁed fatty acid removal, whereas free cholesterol was
not depleted under these conditions. These data provided a
ﬁrst indication that binding of the C1q subunit of C1 to E-
LDL particles involved the unesteriﬁed fatty acids generated
by CEase treatment.
To further investigate this question, model vesicles
containingphosphatidylcholine (PC)and increasing propor-
tions of unesteriﬁed cholesterol and/or linoleic acid were
prepared and tested for their ability to activate C1 [15].
Increasing the amount of linoleic acid increased the C1-
activating potential of the vesicles, yielding about 65%
activation at a 1:1 linoleic acid:PC ratio, and then had the
opposite eﬀect at a 2:1 ratio. In contrast, increasing both
linoleic acid and cholesterol dose-dependently increased the
ability of the vesicles to activate C1, yielding full activation at
a 2:2:1 linoleic acid:cholesterol:PC ratio. Further analyses
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Figure 3: Cosedimentation analysis of the interaction between
the C1q globular domain and artiﬁcial lipid vesicles. Vesicles were
prepared from PC alone, PC:cholesterol (1:2, w/w), PC:linoleic
acid (1:2, w/w), or PC:cholesterol:linoleic acid (1:2:2, w/w/w).
Each type of vesicle was incubated with the C1q globular domain
(C1q GR), and binding was measured from the relative amount
of C1q GR associated with the vesicles in the ultracentrifugation
pellet, as determined by SDS-PAGE analysis of the pellet (P) and
supernatant (S) fractions. Chol: cholesterol; LA: linoleic acid; PC:
phosphatidylcholine (taken from [15], with permission).
were conducted using lipid vesicles containing PC plus
either cholesterol, or linoleic acid, or both cholesterol and
linoleic acid. After incubation of these vesicles with the
C1q globular domain (C1q GR), interaction was assessed by
cosedimentation analysis from the relative amount of C1q
GR sedimenting with the vesicles in the ultracentrifugation
pellet (Figure 3). No binding to vesicles containing PC alone
or PC + cholesterol was detected. A slight but signiﬁcant
binding (about 20%) was observed using vesicles containing
PC+linoleicacid,andthisvalueincreasedto46%whenboth
cholesterol and linoleicacid were present (Figure3).Analysis
of the pellets revealed that linoleic acid was more eﬃciently
incorporated into the vesicles in the presence of cholesterol.
It became clear, therefore, that linoleic acid was the only
ligand recognized by C1q, the enhancing eﬀect exerted by
cholesterol being due to its ability to facilitate incorporation
of free fatty acids into the vesicles. Another indication from
the cosedimentation experiments was that recognition by
C1q of the fatty acids of E-LDL was mediated by its globular
(GR) domains.
5.ElectronMicroscopyofE-LDL-Bound
C1qMolecules
Negative staining electron microscopy was used to visualize
interaction of the whole C1q molecule with E-LDL particles.
Bound C1q molecules were clearly seen to interact with the
particles through their globular domains. In some cases,
most of the 6 globular domains were found to follow the
curvature of the particles (Figure 4(a)), whereas other C1q
molecules interacted through only a few heads (Figure 4(b)).
Some free C1q molecules not interacting with E-LDL
particles could also be identiﬁed (Figure 4(c)).
6.Discussion
The variousexperimentscarriedoutinthepastyearsprovide
clear experimental evidence that, in contrast to native LDL
and oxLDL, E-LDL is endowed with the ability to activate
C1, the multimolecular protease that triggers the classical4 Journal of Lipids
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Figure 4: Electron micrographs of E-LDL-bound C1q molecules. (a, b) Examples of C1q molecules interacting through most of their
globular domains (a) or only a few (b). (c) Representative example of a free C1q molecule (modiﬁed from [15], with permission).
pathway of complement. The observation that native LDL
particles do not activate C1 is consistent with the fact
that these are not recognized by C1q. In contrast, oxLDL
particles are sensed by C1q, with a binding aﬃnity similar
t ot h a td e t e r m i n e df o rE - L D L ;h o w e v e r ,t h e yd on o tt r i g g e r
C1 activation. It appears likely therefore that oxidation
generates C1q binding sites on the LDL surface, but these are
distributed in a manner that does not allow C1 activation.
An alternative explanation is that C1 activation by oxLDL is
eﬃciently prevented by C1 inhibitor, as observed for other
“weak” nonimmune activators of C1 such as DNA and
heparin [17, 18]. In contrast, the fact that E-LDL behaves
as a potent C1 activator in the presence of excess C1
inhibitor strongly suggests that this process observed in vitro
is biologically relevant.
A further major conclusion from these investigations is
that C1 binding to E-LDL particles is mediated by the C1q
globular domains and that these recognize the unesteriﬁed
fatty acid molecules generated by CEase treatment. The
conversion of native LDL into a particle endowed with
C1-activating ability clearly requires prior treatment with
a proteolytic enzyme and then with CEase. In addition
to trypsin used as a model, several proteases (plasmin,
matrix metalloproteases-2, thrombin, tryptase) present in
the atherosclerotic lesions [19, 20] are able to generate E-
LDL particles with high C1-activating ability. Considering
that CEase itself is present in the arterial intima [8, 21],
it appears likely that C1-activating E-LDL particles are
indeed generated in vivo. In agreement with this hypothesis,
electron microscopy analyses show that extensive hydrolysis
of cholesteryl esters by CEase generates large liposome-like
particles [15] similar to those previously described by Chao
et al. [8] and reminiscent of the lipid particles observed in
atherosclerotic lesions [7, 22].
Proteolysis of ApoB-100 appears necessary to allow
access of cholesteryl ester molecules to CEase. Although
no strict correlation was observed between the extent of
ApoB-100 degradation and the C1-activating ability of the
resulting particle, it should be emphasized that the SDS-
PAGE technique used only gives a rough account of the
extent of LDL degradation. The most likely hypothesis is
therefore that proteolytic treatment of the LDL particle dis-
organizes ApoB-100 [8], hence allowing CEase to gain access
to the underlying hydrophobic core containing cholesteryl
esters and triglycerides, resulting in the production of large
amounts of cholesterol and unesteriﬁed fatty acids.
HowC1qsenses fattyacidsontheE-LDLsurface remains
to be determined at the molecular level. However, C1q
bindingisclearlymediatedbyitsglobulardomain,indicating
that, in addition to its numerous ligands already identiﬁed
[23],thisdomain recognizes the polarhead offatty acidsand
therefore possesses a binding site for carboxyl groups. This is
consistent with the known ability of C1q to bind polyanionic
ligands [24], considering that treatment with CEase converts
LDL particles into polyanions. These investigations provide
clear evidence that E-LDL is recognized by C1q, further
establishing the role of this protein as a sensor of altered
self-components. Another modiﬁed form of LDL, acetylated
LDL, was recently shown to be recognized by C1q, as well as
by two other innate immune recognition proteins involved
in activation of the lectin, pathway of complement, mannan-
binding lectin, and L-ﬁcolin [25, 26].
The observation that E-LDL triggers activation of the
classical complement pathway provides further support forJournal of Lipids 5
an implication of complement in atherogenesis. It now
remains to be established whether complement activation
hasaprotectiveeﬀectthroughtheremovalofE-LDLparticles
from atherosclerotic plaques or is proatherogenic because of
the intrinsic ability of the terminal complement pathway to
generate inﬂammatory mediators.
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